Rocchi S.; Tacchetti P.; Pantani L.; Mancuso K.; Rizzello I.; di Giovanni Bezzi C.; Scalese M.; Dozza L.; Marzocchi G.; Martello M.; Barila G.; Antonioli E.; Staderini M.; Buda G.; Petrini M.; Cea M.; Quaresima M.; Furlan A.; Bonalumi A.; Cavo M.; Zamagni E., A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma, «HEMATOLOGICAL ONCOLOGY», 2021, 39, pp. 41 - 50 [articolo]
Gay F.; Musto P.; Rota-Scalabrini D.; Bertamini L.; Belotti A.; Galli M.; Offidani M.; Zamagni E.; Ledda A.; Grasso M.; Ballanti S.; Spadano A.; Cea M.; Patriarca F.; D'Agostino M.; Capra A.; Giuliani N.; de Fabritiis P.; Aquino S.; Palmas A.; Gamberi B.; Zambello R.; Petrucci M.T.; Corradini P.; Cavo M.; Boccadoro M., Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial, «THE LANCET ONCOLOGY», 2021, 22, pp. 1705 - 1720 [articolo]
Sonneveld P.; Dimopoulos M.A.; Beksac M.; van der Holt B.; Aquino S.; Ludwig H.; Zweegman S.; Zander T.; Zamagni E.; Wester R.; Hajek R.; Pantani L.; Dozza L.; Gay F.; Cafro A.; De Rosa L.; Morelli A.; Gregersen H.; Gulbrandsen N.; Cornelisse P.; Troia R.; Oliva S.; van de Velden V.; Wu K.; Ypma P.F.; Bos G.; Levin M.-D.; Pour L.; Driessen C.; Broijl A.; Croockewit A.; Minnema M.C.; Waage A.; Hveding C.; van de Donk N.W.C.J.; Offidani M.; Palumbo G.A.; Spencer A.; Boccadoro M.; Cavo M., Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma, «JOURNAL OF CLINICAL ONCOLOGY», 2021, 39, pp. 3613 - 3622 [articolo]
Mina R.; Bonello F.; Gay F.; Zamagni E.; Boccadoro M., Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case Report, «CLINICAL LYMPHOMA MYELOMA & LEUKEMIA», 2021, 21, pp. e21 - e24 [articolo]
Gentile M.; Specchia G.; Derudas D.; Galli M.; Botta C.; Rocco S.; Conticello C.; Califano C.; Giuliani N.; Mangiacavalli S.; Attingenti E.; Lombardo A.; Brunori M.; Rossi E.; Antonioli E.; Ria R.; Zambello R.; Di Renzo N.; Mele G.; Marcacci G.; Musto P.; Capalbo S.; Cascavilla N.; Cerchione C.; Belotti A.; Criscuolo C.; Uccello G.; Curci P.; Vigna E.; Fraticelli V.; Vincelli D.; Bonalumi A.; Siniscalchi A.; Stocchi R.; Martino M.; Ballanti S.; Gangemi D.; Gagliardi A.; Gamberi B.; Pompa A.; Recchia A.G.; Tripepi G.; Pitino A.; Frigeri F.; Consoli U.; Bringhen S.; Zamagni E.; Patriarca F.; De Stefano V.; Di Raimondo F.; Palmieri S.; Petrucci M.T.; Offidani M.; Boccadoro M.; Cavo M.; Morabito F., Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials, «HAEMATOLOGICA», 2021, 106, pp. 291 - 294 [articolo]Open Access
Tacchetti P.; Rocchi S.; Barbato S.; Zamagni E.; Pantani L.; Mancuso K.; Rizzello I.; Cavo M., Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients, «EXPERT REVIEW OF HEMATOLOGY», 2021, 14, pp. 1085 - 1098 [articolo]
Cavo M.; Tacchetti P.; Zamagni E., Expanding CD38-targeting triplets for relapsed or refractory multiple myeloma, «THE LANCET», 2021, 397, pp. 2311 - 2313 [articolo]
Rosinol L.; Beksac M.; Zamagni E.; Van de Donk N.W.C.J.; Anderson K.C.; Badros A.; Caers J.; Cavo M.; Dimopoulos M.-A.; Dispenzieri A.; Einsele H.; Engelhardt M.; Fernandez de Larrea C.; Gahrton G.; Gay F.; Hajek R.; Hungria V.; Jurczyszyn A.; Kroger N.; Kyle R.A.; Leal da Costa F.; Leleu X.; Lentzsch S.; Mateos M.V.; Merlini G.; Mohty M.; Moreau P.; Rasche L.; Reece D.; Sezer O.; Sonneveld P.; Usmani S.Z.; Vanderkerken K.; Vesole D.H.; Waage A.; Zweegman S.; Richardson P.G.; Blade J., Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations, «BRITISH JOURNAL OF HAEMATOLOGY», 2021, 194, pp. 496 - 507 [articolo]
Zamagni, Elena; Barbato, Simona; Cavo, Michele, How I Treat High-risk Multiple Myeloma, «BLOOD», 2021, blood.2020008733, pp. N/A - N/A [articolo]
Anderson K.C.; Auclair D.; Adam S.J.; Agarwal A.; Anderson M.; Avet-Loiseau H.; Bustoros M.; Chapman J.; Connors D.E.; Dash A.; Bacco A.D.; Du L.; Facon T.; Flores-Montero J.; Gay F.; Ghobrial I.M.; Gormley N.J.; Gupta I.; Higley H.; Hillengass J.; Kanapuru B.; Kazandjian D.; Kelloff G.J.; Kirsch I.R.; Kremer B.; Landgren O.; Lightbody E.; Lomas O.C.; Lonial S.; Mateos M.-V.; de Oca R.M.; Mukundan L.; Munshi N.C.; Odonnell E.K.; Orfao A.; Paiva B.; Patel R.; Pugh T.J.; Ramasamy K.; Ray J.; Roshal M.; Ross J.A.; Sigman C.C.; Thoren K.L.; Trudel S.; Ulaner G.; Valente N.; Weiss B.M.; Zamagni E.; Kumar S.K., Minimal residual disease in Myeloma: Application for clinical care and new drug registration, «CLINICAL CANCER RESEARCH», 2021, 27, pp. 5195 - 5212 [articolo]Open Access
Solli, Vincenza; Poletti, Andrea; Borsi, Enrica; Martello, Marina; Pantani, Lucia; Armuzzi, Silvia; Vigliotta, Ilaria; Zamagni, Elena; Tacchetti, Paola; Rocchi, Serena; Mancuso, Katia; Mazzocchetti, Gaia; Taurisano, Barbara; Pistis, Ignazia; Cavo, Michele; Terragna, Carolina, OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma, «CLINICAL LYMPHOMA MYELOMA & LEUKEMIA», 2021, 21, pp. S4 - S5 [abstract]
Andrea Poletti, Vincenza Solli, Gaia Mazzocchetti, Marina Martello, Enrica Borsi, Silvia Armuzzi, Ilaria Vigliotta, Barbara Taurisano, Elena Zamagni, Lucia Pantani, Paola Tacchetti, Katia Mancuso, Serena Rocchi , Carolina Terragna , Michele Cavo, OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival, in: Clinical Lymphoma Myeloma and Leukemia. Volume 21, Supplement 2, October 2021, 2021, pp. S35 - S36 (atti di: 18th International Myeloma Workshop, Vienna, Austria, September 8 - 11, 2021) [Contributo in Atti di convegno]
Jamet B.; Morvan L.; Nanni C.; Michaud A.-V.; Bailly C.; Chauvie S.; Moreau P.; Touzeau C.; Zamagni E.; Bodet-Milin C.; Kraeber-Bodere F.; Mateus D.; Carlier T., Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials, «EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING», 2021, 48, pp. 1005 - 1015 [articolo]
Zamagni, E.; Dhanasiri, S.; Ghale, A.; Moore, A.; Roussel, M., Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens, «LEUKEMIA & LYMPHOMA», 2021, 62, pp. 2492 - 2501 [articolo]Open Access
Zamagni E.; Nanni C.; Dozza L.; Carlier T.; Bailly C.; Tacchetti P.; Versari A.; Chauvie S.; Gallamini A.; Gamberi B.; Caillot D.; Patriarca F.; Macro M.; Boccadoro M.; Garderet L.; Barbato S.; Fanti S.; Perrot A.; Gay F.; Sonneveld P.; Karlin L.; Cavo M.; Bodet-Milin C.; Moreau P.; Kraeber-Bodere F., Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma, «JOURNAL OF CLINICAL ONCOLOGY», 2021, 39, pp. 116 - 125 [articolo]
